ストックスクリーナーアプリを入手
9.83
3.82%
0.31
Immatics N V (IMTX) 最新ニュース
Immatics: PRAME Is Becoming More Than A Single-Asset Story (NASDAQ:IMTX) - Seeking Alpha
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
TD Cowen initiates coverage of Immatics NV (IMTX) with buy recommendation - MSN
The Technical Signals Behind (IMTX) That Institutions Follow - Stock Traders Daily
IMTX SEC FilingsImmatics N.V 10-K, 10-Q, 8-K Forms - Stock Titan
Immatics NV Stock Hits Day Low of $9.81 Amid Price Pressure - MarketsMojo
Immatics (IMTX) Faces Headwinds as Shares Decline 3.83% Amid Sector RotationStock News - newsline.com
Immatics N.V. (IMTX) Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Clinical InvestmentNegative Surprise Momentum - newsline.com
Immatics schedules annual general meeting for June 18 in Amsterdam By Investing.com - Investing.com India
Immatics Calls 2026 Annual General Meeting, Sets Record Date and Details New Incentive Plan - TipRanks
Immatics schedules annual general meeting for June 18 in Amsterdam - Investing.com
Immatics (IMTX) schedules 2026 AGM with vote on new stock plan - Stock Titan
Immatics NV stock (NL0015255052): ASCO data spotlight PRAME cell therapy as Nasdaq shares hover arou - AD HOC NEWS
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting - Investing News Network
Immatics Showcases Strong Phase 1 Data for PRAME and MAGEA4/8 TCR Programs at ASCO 2026 - TipRanks
Immatics (NASDAQ: IMTX) shows promising PRAME and MAGEA4/8 trial results at ASCO 2026 - Stock Titan
Immatics Presents Clinical Activity and Response Dynamics - GlobeNewswire
Immatics N.V. Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D Investment - The Legal Advocate
Immatics NV stock (NL0015255052): ASCO 2026 data on IMA401 and IMA203CD8 put TCR pipeline in focus - AD HOC NEWS
Immatics (IMTX) Shares Promising Phase 1 Results for IMA203CD8 T - GuruFocus
Immatics (IMTX) Unveils Promising Results from Phase 1 Trial of IMA401 - GuruFocus
Immatics (IMTX) Shares Promising Phase 1 Results for IMA203CD8 Therapy - GuruFocus
Immatics announces updated Phase 1 data for its Prame TCR T-cell therapy - TipRanks
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates as Biotech Continues DevelopmentEPS Miss Report - The Legal Advocate
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer - markets.businessinsider.com
Immatics Announces Promising Clinical Data for IMA401 in Solid Tumors, Including Head and Neck Cancer, Ahead of ASCO Presentation - Quiver Quantitative
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at - GlobeNewswire
Precision Trading with Immatics N.v. (IMTX) Risk Zones - Stock Traders Daily
Immatics N.V. Reports Promising Phase 1 Results for IMA203CD8 PRAME Cell Therapy in Gynecologic and Synovial Sarcoma Cancers - Quiver Quantitative
Phase 1 cell therapy shows 63% response in hard-to-treat gynecologic cancers - Stock Titan
Immatics Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues Pipeline Progress - newsline.com
Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Immatics (IMTX) Gains Ground: Biotech Stock Tests Key Resistance at $11.96Diamond Pattern - The Legal Advocate
Immatics N.V. (IMTX) Surges 5% as Biotech Sentiment Improves; Key Resistance at $12.20 in FocusRunaway Gap - Newser
Immatics (IMTX) Surges 5%: Breaking Resistance or Facing a Ceiling?Throwback Trade - Newser
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates as Clinical Progress Drives Share Gains - newsline.com
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 5% Amid Pipeline ProgressQuarterly Profit Report - newsline.com
Immatics N.V. (IMTX) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Clinical ProgressVerified Analyst Reports - Newser
Immatics NV stock (NL0015255052): Q1 loss widens while cancer pipeline advances - AD HOC NEWS
How Investors May Respond To Immatics (IMTX) Wider Q1 Loss And Rising Funding Needs - simplywall.st
IMTX Maintained by Chardan Capital -- Price Target Stands at $25 - GuruFocus
Technical Reactions to IMTX Trends in Macro Strategies - Stock Traders Daily
Immatics N.V. (IMTX) Q1 2026 Earnings: Miss Sparks Concern{璐㈡姤鍓爣棰榼 - Newser
Why Is Immatics N.V. (IMTX) Stock Down Today? - Meyka
Immatics N.V. (IMTX) Q1 2026 Results Fall Short — EPS $-0.43, Revenue $N/A{璐㈡姤鍓爣棰榼 - Newser
Immatics NV stock (NL0015255052): T. Rowe Price discloses 16.1% stake – what it means for investor - AD HOC NEWS
[SCHEDULE 13G/A] Immatics N.V. Amended Passive Investment Disclosure - Stock Titan
TD Bank (IMTX) discloses 7.44M shares, 5.5% stake (Schedule 13G) - Stock Titan
T. Rowe Price reports 16.1% stake in IMMATICS (NASDAQ: IMTX) - Stock Titan
Immatics N.V. (IMTX): RTW reports 12.87M shares, 9.6% stake - Stock Titan
4.93%
0.20%
大文字化:
|
ボリューム (24 時間):